Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase II trial of Avicine in prostate cancer announced

July 17, 1998

AltaRex initiates second phase II trial of OvaRex

July 16, 1998

Theragyn phase III testing will begin in U.K.

July 13, 1998

Regressin holds promise for a wide range of cancers, new data indicates

July 13, 1998

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

July 10, 1998

NeoPharm scales up IL13-PE38QQR manufacturing

July 10, 1998

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

July 6, 1998

Herceptin licensed to Roche for most markets

July 6, 1998

Phase II retreatment trial with Bexxar commences

June 30, 1998

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

June 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...